INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma

被引：0
|
作者：
Weber, Jeffrey S.
Luke, Jason J.
Carlino, Matteo S.
Khattak, Muhammad Adnan
Meehan, Robert S.
Brown, Michelle
Zhang, Jinchun
Krepler, Clemens
Duic, J. Paul
Long, Georgina V.
机构：
[1] NYU Langone Med Ctr, New York, NY USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Sydney, Sydney Med Sch, Fac Med & Hlth Sci, Camperdown, NSW, Australia
[4] Melanoma Inst Australia, Sydney, NSW, Australia
[5] Westmead & Blacktown Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW, Australia
[6] One Clin Res, Perth, WA, Australia
[7] Edith Cowan Univ, Perth, WA, Australia
[8] Moderna Inc, Cambridge, MA USA
[9] Merck & Co Inc, Rahway, NJ USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9616
引用
收藏
页数：1
相关论文
共 33 条
  • [31] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
    Eggermont, A. M. M.
    Blank, C. U.
    Mandala', M.
    Long, G. V.
    Atkinson, V.
    Dalle, S.
    Haydon, A. M.
    Meshcheryakov, A.
    Khattak, A.
    Carlino, M.
    Sandhu, S.
    Sarda, S. Puig
    Ascierto, P. A.
    van Akkooi, A. C. J.
    Krepler, C.
    Ibrahim, N.
    Marreaud, S. I.
    Kicinski, M.
    Suciu, S.
    Robert, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1175 - S1175
  • [32] Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial
    Coens, C.
    Bottomley, A.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A.
    Lichinitser, M.
    Khattak, A.
    Carlino, M. S.
    Sandhu, S. K.
    Larkin, J.
    Puig Sarda, S.
    Ascierto, P. A.
    Schadendorf, D.
    Ibrahim, N.
    Suciu, S.
    Robert, C.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2018, 29 : 456 - 456
  • [33] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
    Eggermont, Alexander M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew Mark
    Meshcheryakov, Andrey
    Khattak, Muhammad
    Carlino, Matteo S.
    Sandhu, Shahneen Kaur
    Puig, Susana
    Ascierto, Paolo Antonio
    Christopher, Alexander
    Van Akkooi, Jonathan
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
1234